D37.09 Insurance Policy Changes

ICD-10 D37.09 is officially defined as "Neoplasm of uncertain behavior of other specified sites of the oral cavity." code D37.09 is referenced in 5 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code D37.09 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 23, 2026Medium impact
Oral and Esophageal Brush Biopsy (CPB 0686, reviewed 2026-10-15)
Aetna Clinical Policy Bulletin 0686 on oral and esophageal brush biopsy was last reviewed on 10/15/2026. It considers oral brush biopsy (OralCDx) with or without MAGE-A or GLUT-1 staining, esophageal brush biopsy (WATS3D, formerly EndoCDx), DNA-image cytometry, RNA-based oral brush biopsy, salivary miRNAs and esophageal balloon cytologic sampling experimental, investigational or unproven because their effectiveness has not been established, for screening, diagnosis or surveillance. The policy lists CPT 88104 and 99000, HCPCS D0486 and D7288, and several ICD-10 codes, including Z12.81, as not covered for the indications it lists.
Aetna · Identified Oct 10, 2026Medium impact
Radiofrequency Tumor Ablation (CPB 0492, reviewed 2026-10-05)
Aetna considers radiofrequency ablation (RFA) medically necessary for indications that include colorectal cancer liver metastases, colorectal cancer lung metastases of 5 cm or less where the primary colorectal tumor has been resected for cure (R0 resection), malignant lung masses in persons who are not candidates for surgical intervention, solitary hepatocellular carcinoma of 5 cm or less or multinodular early-stage HCC in members who are ineligible for or decline surgical resection or transplantation, renal cell carcinoma up to 4 cm in high-risk surgical candidates or in persons with renal insufficiency or a solitary kidney, and osteoid osteoma in individuals who remain symptomatic despite NSAIDs. Aetna considers RFA experimental, investigational, or unproven for combined RFA with transarterial chemoembolization for intermediate-stage hepatocellular carcinoma, combined endoluminal RFA and stenting for malignant biliary obstruction or stricture, combined RFA and vertebral cement augmentation for spinal metastases, endoscopic ultrasound-guided RFA for aldosterone-producing adenomas, and all other indications, including curative treatment of primary or metastatic malignant neoplasms in persons able to tolerate surgical resection, biliary obstructions or strictures, renal cysts, renal angiomyolipomas, Brunner's gland hyperplasia, and unresectable localized recurrent thyroid cancers without distant metastases.
Aetna · Identified Aug 16, 2026Medium impact
Ribavirin for Inhalation Use (CPB 0155, reviewed 2026-04-21)
Aetna considers ribavirin for inhalation medically necessary for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus (RSV). Aetna considers all other indications experimental, investigational, or unproven, including the cationic liposome encapsulated ribavirin spray for the treatment of acute pneumonia. Ribavirin for inhalation is not indicated for use in adults.
Aetna · Identified Aug 12, 2026Medium impact
Oral Screening and Lesion Identification Systems (CPB 0760, reviewed 2025-12-02)
Oral screening and lesion identification systems are considered experimental, investigational, or unproven because the effectiveness of these approaches has not been established. This covers artificial intelligence-based technology, Epstein-Barr virus testing for screening for oral squamous cell carcinoma, oral HPV testing (for example the OraRisk HPV Salivary DNA Test) for all indications, several salivary biomarker tests for screening and detecting oral squamous cell carcinoma, salivary hyper-methylated DNA biomarkers for detecting oral cancer, salivary metabolite biomarkers, and tumor-derived exosomal biomarkers from a liquid biopsy for early detection of oral cancer. For early detection of oral cancer and other indications, the following are also considered experimental, investigational, or unproven: chemiluminescence, confocal laser endomicroscopy, diffuse reflectance spectroscopy, fluorescence spectroscopy, MOP genetic testing, narrow band imaging, the optical filter for auto-fluorescence glasses (GOCCLES), optical fluorescence imaging, oral lesion identification systems (including the Dentlight Oral Exam Light Kit, Microlux DL, Orascoptic DK, Sapphire Plus, TRIMIRA Identafi 3000, ViziLite-Blue and VELscope), Straticyte, and wide-field and high-resolution in-vivo imaging. The listed CPT and HCPCS codes are not covered for the indications listed in CPB 0760, and the listed ICD-10 codes are not covered for those indications either.
Aetna · Identified Aug 12, 2026Medium impact
Oral and Esophageal Brush Biopsy (CPB 0686, reviewed 2025-10-15)
Aetna considers oral brush biopsy (OralCDx Brush Test), with or without MAGE-A or GLUT-1 staining, experimental, investigational or unproven for screening, diagnosis or surveillance of cancerous or pre-cancerous oral lesions. The same designation applies to esophageal brush biopsy with WATS3D (formerly EndoCDx) for screening, diagnosis or surveillance of cancerous or pre-cancerous esophageal lesions, to DNA-image cytometry of brush biopsies for early detection of oral malignancy, to RNA-based oral brush biopsy, to salivary miRNAs as liquid biopsy biomarkers for oropharyngeal squamous cell carcinoma, and to use of an esophageal balloon for circumferential esophageal cytologic sampling. The policy lists CPT 88104 and 99000 and HCPCS D0486 and D7288 among codes not covered for the indications it lists.

Watch D37.09

Get one email when a payer policy names D37.09, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code D37.09?

There are 5 tracked policy changes affecting code D37.09, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code D37.09?

Payers that have issued tracked updates for code D37.09 include: Aetna.

How do I get notified when code D37.09 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code D37.09. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code D37.09?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Oral and Esophageal Brush Biopsy (CPB 0686, reviewed 2026-10-15)

Radiofrequency Tumor Ablation (CPB 0492, reviewed 2026-10-05)

Ribavirin for Inhalation Use (CPB 0155, reviewed 2026-04-21)

Oral Screening and Lesion Identification Systems (CPB 0760, reviewed 2025-12-02)

Oral and Esophageal Brush Biopsy (CPB 0686, reviewed 2025-10-15)

What insurance policy changes affect code D37.09?

Which payers have updated policy for code D37.09?

How do I get notified when code D37.09 policy changes?

Why do payers change policies for code D37.09?